tbuckley/cabot-search huggingface dataset:
Oral administration of Bifidobacterium breve improves anti-angiogenic drugs-derived oral mucosal wound healing impairment via upregulation of interleukin-10
Authors: Qingxiang Li, Yuke Li, Qiao Qiao, Ning Zhao, Yuanning Yang, Lin Wang, Yifei Wang, Chuanbin Guo, Yuxing Guo
Journal: International Journal of Oral Science (2023)

Abstract Recent studies have suggested that long-term application of anti-angiogenic drugs may impair oral mucosal wound healing. This study investigated the effect of sunitinib on oral mucosal healing impairment in mice and the therapeutic potential of Bifidobacterium breve ( B. breve ). A mouse hard palate mucosal defect model was used to investigate the influence of sunitinib and/or zoledronate on wound healing. The volume and density of the bone under the mucosal defect were assessed by micro-computed tomography (micro-CT). Inflammatory factors were detected by protein microarray analysis and enzyme-linked immunosorbent assay (ELISA). The senescence and biological functions were tested in oral mucosal stem cells (OMSCs) treated with sunitinib. Ligated loop experiments were used to investigate the effect of oral B. breve . Neutralizing antibody for interleukin-10 (IL-10) was used to prove the critical role of IL-10 in the pro-healing process derived from B. breve . Results showed that sunitinib caused oral mucosal wound healing impairment in mice. In vitro, sunitinib induced cellular senescence in OMSCs and affected biological functions such as proliferation, migration, and differentiation. Oral administration of B. breve reduced oral mucosal inflammation and promoted wound healing via intestinal dendritic cells (DCs)-derived IL-10. IL-10 reversed cellular senescence caused by sunitinib in OMSCs, and IL-10 neutralizing antibody blocked the ameliorative effect of B. breve on oral mucosal wound healing under sunitinib treatment conditions. In conclusion, sunitinib induces cellular senescence in OMSCs and causes oral mucosal wound healing impairment and oral administration of B. breve could improve wound healing impairment via intestinal DCs-derived IL-10.
Matrix Metalloproteinase-7 in Urinary Extracellular Vesicles Identifies Rapid Disease Progression in Autosomal Dominant Polycystic Kidney Disease
Authors: Martijn H. van Heugten, Charles J. Blijdorp, Sita Arjune, Hester van Willigenburg, Karel Bezstarosti, Jeroen A.A. Demmers, Usha Musterd-Bhaggoe, Esther Meijer, Ron T. Gansevoort, Robert Zietse, Sikander Hayat, Rafael Kramann, Roman-Ulrich Müller, Mahdi Salih, Ewout J. Hoorn
Journal: Journal of the American Society of Nephrology (2023)

Significance Statement There is an unmet need for biomarkers of disease progression in autosomal dominant polycystic kidney disease (ADPKD). This study investigated urinary extracellular vesicles (uEVs) as a source of such biomarkers. Proteomic analysis of uEVs identified matrix metalloproteinase 7 (MMP-7) as a biomarker predictive of rapid disease progression. In validation studies, MMP-7 was predictive in uEVs but not in whole urine, possibly because uEVs are primarily secreted by tubular epithelial cells. Indeed, single-nucleus RNA sequencing showed that MMP-7 was especially increased in proximal tubule and thick ascending limb cells, which were further characterized by a profibrotic phenotype. Together, these data suggest that MMP-7 is a biologically plausible and promising uEV biomarker for rapid disease progression in ADPKD. Background In ADPKD, there is an unmet need for early markers of rapid disease progression to facilitate counseling and selection for kidney-protective therapy. Our aim was to identify markers for rapid disease progression in uEVs. Methods Six paired case–control groups ( n =10–59/group) of cases with rapid disease progression and controls with stable disease were formed from two independent ADPKD cohorts, with matching by age, sex, total kidney volume, and genetic variant. Candidate uEV biomarkers were identified by mass spectrometry and further analyzed using immunoblotting and an ELISA. Single-nucleus RNA sequencing of healthy and ADPKD tissue was used to identify the cellular origin of the uEV biomarker. Results In the discovery proteomics experiments, the protein abundance of MMP-7 was significantly higher in uEVs of patients with rapid disease progression compared with stable disease. In the validation groups, a significant &gt;2-fold increase in uEV-MMP-7 in patients with rapid disease progression was confirmed using immunoblotting. By contrast, no significant difference in MMP-7 was found in whole urine using ELISA. Compared with healthy kidney tissue, ADPKD tissue had significantly higher MMP-7 expression in proximal tubule and thick ascending limb cells with a profibrotic phenotype. Conclusions Among patients with ADPKD, rapid disease progressors have higher uEV-associated MMP-7. Our findings also suggest that MMP-7 is a biologically plausible biomarker for more rapid disease progression.
Local Ancestry at the Major Histocompatibility Complex Region is Not a Major Contributor to Disease Heterogeneity in a Multiethnic Lupus Cohort
Authors: Olivia Solomon, Cristina M. Lanata, Cameron Adams, Joanne Nititham, Kimberly E. Taylor, Sharon A. Chung, Jinoos Yazdany, Maria Dall'Era, Bernado A. Pons‐Estel, Teresa Tusié‐Luna, Betty Tsao, Eric Morand, Marta E. Alarcón‐Riquelme, Lisa F. Barcellos, Lindsey A. Criswell
Journal: Arthritis & Rheumatology (2023)

Objective Systemic lupus erythematosus (SLE) is an autoimmune disease resulting in debilitating clinical manifestations that vary in severity by race and ethnicity with a disproportionate burden in African American, Mestizo, and Asian populations compared with populations of European descent. Differences in global and local genetic ancestry may shed light on the underlying mechanisms contributing to these disparities, including increased prevalence of lupus nephritis, younger age of symptom onset, and presence of autoantibodies. Methods A total of 1,139 European, African American, and Mestizos patients with SLE were genotyped using the Affymetrix LAT1 World array. Global ancestry proportions were estimated using ADMIXTURE, and local ancestry was estimated using RFMIXv2.0. We investigated associations between lupus nephritis, age at onset, and autoantibody status with both global and local ancestry proportions within the Major Histocompatibility Complex region. Results Our results showed small effect sizes that did not meet the threshold for statistical significance for global or local ancestry proportions in either African American or Mestizo patients with SLE who presented with the clinical manifestations of interest compared with those who did not. Conclusion These findings suggest that local genetic ancestry within the Major Histocompatibility Complex region is not a major contributor to these SLE manifestations among patients with SLE from admixed populations.
Targeting gut microbiota in aging-related cardiovascular dysfunction: focus on the mechanisms
Authors: Siqi Liu, Yufeng He, Yali Zhang, Zhaolun Zhang, Keming Huang, Li Deng, Bin Liao, Yi Zhong, Jian Feng
Journal: Gut Microbes (2023)

The global population is aging and age-related cardiovascular disease is increasing. Even after controlling for cardiovascular risk factors, readmission and mortality rates remain high. In recent years, more and more in-depth studies have found that the composition of the gut microbiota and its metabolites, such as trimethylamine N-oxide (TMAO), bile acids (BAs), and short-chain fatty acids (SCFAs), affect the occurrence and development of age-related cardiovascular diseases through a variety of molecular pathways, providing a new target for therapy. In this review, we discuss the relationship between the gut microbiota and age-related cardiovascular diseases, and propose that the gut microbiota could be a new therapeutic target for preventing and treating cardiovascular diseases.
Different Immunologic Profiles Are Associated With Distinct Clinical Phenotypes in Longitudinally Observed Patients With Systemic Lupus Erythematosus
Authors: Kieran Manion, Carolina Muñoz‐Grajales, Michael Kim, Eshetu Atenafu, Zoha Faheem, Dafna D. Gladman, Murray Urowitz, Zahi Touma, Joan E. Wither
Journal: Arthritis & Rheumatology (2023)

Objective The aim of this study was to determine the immunologic profile associated with disease flares in patients with systemic lupus erythematosus (SLE) and to investigate the clinical significance of any differences observed between patients during and following a flare. Methods Multiparameter flow cytometry was used to examine 47 immune populations within the peripheral blood of 16 healthy controls, 25 patients with clinically quiescent SLE, and 46 patients with SLE experiencing a flare at baseline and at 6‐ and 12‐month follow‐up visits. Unsupervised clustering was used to identify patients with similar immune profiles and to track changes over time. Parametric or nonparametric statistics were used when appropriate to assess the association of cellular phenotypes with clinical and laboratory parameters. Results Five clusters of patients were identified that variably contained patients with active and quiescent SLE, and that had distinct clinical phenotypes. Patients characterized by increased T peripheral helper, activated B, and age‐associated B cells were the most likely to be flaring at baseline, as well as the most likely to remain active or flare over the subsequent year if they acquired or retained this phenotype at follow‐up. In contrast, patients who had increased T helper (T h ) cells in the absence of B cell changes, or who had increased T h 1 cells and innate immune populations, mostly developed quiescent SLE on follow‐up. A significant proportion of patients with SLE had depletion of many immune populations at flare and only showed increases in these populations post‐flare. Conclusion Cellular phenotyping of patients with SLE reveals several distinct immunologic profiles that may help to stratify patients with regard to prognosis and treatment. image
Biological biomarkers of oral cancer
Authors: Allan Radaic, Pachiyappan Kamarajan, Alex Cho, Sandy Wang, Guo‐Chin Hung, Fereshteh Najarzadegan, David T. Wong, Hung Ton‐That, Cun‐Yu Wang, Yvonne L. Kapila
Journal: Periodontology 2000 (2023)

The oral squamous cell carcinoma (OSCC) 5 year survival rate of 41% has marginally improved in the last few years, with less than a 1% improvement per year from 2005 to 2017, with higher survival rates when detected at early stages. Based on histopathological grading of oral dysplasia, it is estimated that severe dysplasia has a malignant transformation rate of 7%-50%. Despite these numbers, oral dysplasia grading does not reliably predict its clinical behavior. Thus, more accurate markers predicting oral dysplasia progression to cancer would enable better targeting of these lesions for closer follow-up, especially in the early stages of the disease. In this context, molecular biomarkers derived from genetics, proteins, and metabolites play key roles in clinical oncology. These molecular signatures can help predict the likelihood of OSCC development and/or progression and have the potential to detect the disease at an early stage and, support treatment decision-making and predict treatment responsiveness. Also, identifying reliable biomarkers for OSCC detection that can be obtained non-invasively would enhance management of OSCC. This review will discuss biomarkers for OSCC that have emerged from different biological areas, including genomics, transcriptomics, proteomics, metabolomics, immunomics, and microbiomics.
Short-Term Exposure to Ambient Air Pollution and Influenza: A Multicity Study in China
Authors: Lin-Jie Yu, Xin-Lou Li, Yan-He Wang, Hai-Yang Zhang, Shi-Man Ruan, Bao-Gui Jiang, Qiang Xu, Yan-Song Sun, Li-Ping Wang, Wei Liu, Yang Yang, Li-Qun Fang
Journal: Environmental Health Perspectives (2023)

Air pollution is a major risk factor for planetary health and has long been suspected of predisposing humans to respiratory diseases induced by pathogens like influenza viruses. However, epidemiological evidence remains elusive due to lack of longitudinal data from large cohorts.
9. Pharmacologic Approaches to Glycemic Treatment: <i>Standards of Care in Diabetes—2024</i>
Authors: Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, Dennis Bruemmer, Billy S. Collins, Laya Ekhlaspour, Jason L. Gaglia, Marisa E. Hilliard, Eric L. Johnson, Kamlesh Khunti, Ildiko Lingvay, Glenn Matfin, Rozalina G. McCoy, Mary Lou Perry, Scott J. Pilla, Sarit Polsky, Priya Prahalad, Richard E. Pratley, Alissa R. Segal, Jane Jeffrie Seley, Robert C. Stanton, Robert A. Gabbay
Journal: Diabetes Care (2023)

The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
12. Retinopathy, Neuropathy, and Foot Care: <i>Standards of Care in Diabetes—2024</i>
Authors: Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, Dennis Bruemmer, Billy S. Collins, Laya Ekhlaspour, Christopher H. Gibbons, John M. Giurini, Marisa E. Hilliard, Eric L. Johnson, Kamlesh Khunti, Ildiko Lingvay, Glenn Matfin, Rozalina G. McCoy, Mary Lou Perry, Scott J. Pilla, Sarit Polsky, Priya Prahalad, Richard E. Pratley, Alissa R. Segal, Jane Jeffrie Seley, Paolo S. Silva, Robert C. Stanton, Robert A. Gabbay
Journal: Diabetes Care (2023)

The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
17. Diabetes Advocacy: <i>Standards of Care in Diabetes—2024</i>
Authors: Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, Dennis Bruemmer, Billy S. Collins, Laya Ekhlaspour, Marisa E. Hilliard, Eric L. Johnson, Kamlesh Khunti, Ildiko Lingvay, Glenn Matfin, Rozalina G. McCoy, Lisa Murdock, Mary Lou Perry, Scott J. Pilla, Sarit Polsky, Priya Prahalad, Richard E. Pratley, Alissa R. Segal, Jane Jeffrie Seley, Robert C. Stanton, Crystal C. Woodward, Robert A. Gabbay
Journal: Diabetes Care (2023)

The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
1. Improving Care and Promoting Health in Populations: <i>Standards of Care in Diabetes—2024</i>
Authors: Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, Dennis Bruemmer, Billy S. Collins, Laya Ekhlaspour, Marisa E. Hilliard, Eric L. Johnson, Kamlesh Khunti, Ildiko Lingvay, Glenn Matfin, Rozalina G. McCoy, Mary Lou Perry, Scott J. Pilla, Sarit Polsky, Priya Prahalad, Richard E. Pratley, Alissa R. Segal, Jane Jeffrie Seley, Robert C. Stanton, Robert A. Gabbay
Journal: Diabetes Care (2023)

The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at https://professional.diabetes.org/SOC.
Author Correction: CD133+ endothelial-like stem cells restore neovascularization and promote longevity in progeroid and naturally aged mice
Authors: Shimin Sun, Yuan Meng, Mingying Li, Xiaolong Tang, Wenjing Hu, Weiwei Wu, Guo Li, Qiuxiang Pang, Wengong Wang, Baohua Liu
Journal: Nature Aging (2023)
Re: Which Patients with Metastatic Hormone-sensitive Prostate Cancer Benefit from Docetaxel: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Trials
Authors: Daniele Raggi, Antonio Cigliola, Chiara Mercinelli, Damiano Patanè, Valentina Tateo, Carlo Bosi, Emanuele Crupi, Giorgio Gandaglia, Alberto Briganti, Andrea Necchi
Journal: European Urology (2023)
Reply to Andrew T. Gabrielson, Logan Galansky, and Heather N. Di Carlo’s Letter to the Editor re: William Morello, Esra Baskin, Augustina Jankauskiene, et al. Antibiotic Prophylaxis in Infants with Grade III, IV, or V Vesicoureteral Reflux. N Engl J Med 2023;389:987–97
Authors: William Morello, Giuseppe Puccio, Emanuele Proverbio, Giovanni Montini
Journal: European Urology (2023)
Reply to Madhur Anand, Bela Jain, and Swati Aggarwal’s Letter to the Editor re: Rudolf A. Werner, Philipp E. Hartrampf, Wolfgang P. Fendler, et al. Prostate-Specific Membrane Antigen Reporting and Data System Version 2.0. Eur Urol 2023;84:491–502
Authors: Philipp E. Hartrampf, Steven P. Rowe, Martin G. Pomper, Takahiro Higuchi, Michael A. Gorin, Rudolf A. Werner
Journal: European Urology (2023)
High Rate of Passenger Lymphocyte Syndrome after ABO Minor Incompatible Lung Transplantation
Authors: Mirjam M. Kohl, Stefan Schwarz, Peter Jaksch, Gabriella Muraközy, Martin Kurz, Marlies Schönbacher, Alexander Tolios, Florian Frommlet, Konrad Hoetzenecker, Günther F. Körmöczi
Journal: American Journal of Respiratory and Critical Care Medicine (2023)

Passenger lymphocyte syndrome (PLS) may complicate minor ABO mismatched lung transplantation (LuTX) via donor-derived red cell antibody-induced hemolysis.
Butyrate reduces adherent-invasive <i>E. coli</i> -evoked disruption of epithelial mitochondrial morphology and barrier function: involvement of free fatty acid receptor 3
Authors: Samira A. Hamed, Armaan Mohan, Saranya Navaneetha Krishnan, Arthur Wang, Marija Drikic, Nicole L. Prince, Ian A. Lewis, Jane Shearer, Åsa V. Keita, Johan D. Söderholm, Timothy E. Shutt, Derek M. McKay
Journal: Gut Microbes (2023)

Gut bacteria provide benefits to the host and have been implicated in inflammatory bowel disease (IBD), where adherent-invasive E. coli (AIEC) pathobionts (e.g., strain LF82) are associated with Crohn's disease. E. coli-LF82 causes fragmentation of the epithelial mitochondrial network, leading to increased epithelial permeability. We hypothesized that butyrate would limit the epithelial mitochondrial disruption caused by E. coli-LF82. Human colonic organoids and the T84 epithelial cell line infected with E. coli-LF82 (MOI = 100, 4 h) showed a significant increase in mitochondrial network fission that was reduced by butyrate (10 mM) co-treatment. Butyrate reduced the loss of mitochondrial membrane potential caused by E. coli-LF82 and increased expression of PGC-1α mRNA, the master regulator of mitochondrial biogenesis. Metabolomics revealed that butyrate significantly altered E. coli-LF82 central carbon metabolism leading to diminished glucose uptake and increased succinate secretion. Correlating with preservation of mitochondrial network form/function, butyrate reduced E. coli-LF82 transcytosis across T84-cell monolayers. The use of the G-protein inhibitor, pertussis toxin, implicated GPCR signaling as critical to the effect of butyrate, and the free fatty acid receptor three (FFAR3, GPR41) agonist, AR420626, reproduced butyrate's effect in terms of ameliorating the loss of barrier function and reducing the mitochondrial fragmentation observed in E. coli-LF82 infected T84-cells and organoids. These data indicate that butyrate helps maintain epithelial mitochondrial form/function when challenged by E. coli-LF82 and that this occurs, at least in part, via FFAR3. Thus, loss of butyrate-producing bacteria in IBD in the context of pathobionts would contribute to loss of epithelial mitochondrial and barrier functions that could evoke disease and/or exaggerate a low-grade inflammation.
Mesoaccumbal glutamate neurons drive reward via glutamate release but aversion via dopamine co-release
Authors: Shelley M. Warlow, Sarthak M. Singhal, Nick G. Hollon, Lauren Faget, Dina S. Dowlat, Vivien Zell, Avery C. Hunker, Larry S. Zweifel, Thomas S. Hnasko
Journal: Neuron (2023)
Development of a Practical Nomogram for Personalized Anemia Management in Patients Treated with Ataxia Telangiectasia and Rad3-related Inhibitor Camonsertib
Authors: Ezra Rosen, Timothy A. Yap, Elizabeth K. Lee, Martin Højgaard, Niharika B. Mettu, Stephanie Lheureux, Benedito A. Carneiro, Ruth Plummer, Adrian J. Fretland, Danielle Ulanet, Yi Xu, Robin McDougall, Maria Koehler, Elisa Fontana
Journal: Clinical Cancer Research (2023)

Camonsertib is a highly selective and potent inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase. Dose-dependent anemia is a class-related on-target adverse event often requiring dose modifications. Individual patient risk factors for the development of significant anemia complicate the selection of a "one-size-fits-all" ATR inhibitor (ATRi) dose and schedule, possibly leading to suboptimal therapeutic doses in patients at low risk of anemia. We evaluated whether early predictors of anemia could be identified to ultimately inform a personalized dose-modification approach.